Concerns over the Iran war intensified again, pushing New York oil futures above USD80 per barrel at one point, and leading to a sell-off in US stocks on Thursday.

The DJIA tumbled incessantly, down as much as 1,162 points or 2.4% at its lowest, and eventually closed down 784 points or 1.6%, at 47,954. The Nasdaq's downswing was relatively mild, ending down 58 points or 0.3%, at 22,748. The S&P 500 finished down 38 points or 0.6%, at 6,830.

Traditional stocks were subdued, with Boeing (BA.US) down 2.3% and Caterpillar (CAT.US) 3.5%. Banks JP Morgan (JPM.US) and Morgan Stanley (MS.US) sagged 2-3%.

The US plans to tighten AI chip export controls, requiring companies like Nvidia (NVDA.US) to obtain government approval before shipping globally. Nvidia closed up 0.2% after fluctuations, while Micron (MU.US) and AMD (AMD.US) lost about 1%.

Techs traded mixed, with Apple (AAPL.US) and Meta (META.US) down about 1%, and Microsoft (MSFT.US) up 1.4% against the market trend, and Amazon (AMZN.US) also up 1%.

(sw/t)~

AASTOCKS Financial News
Website: www.aastocks.com

The US government is weighing further tightening controls on the export of AI chips, potentially requiring companies to obtain approval from Washington before exporting AI chips to any location worldwide, Bloomberg reported.

Spurred by the news, chip stocks came under pressure. NVIDIA (NVDA.US) plunged over 1.5%. AMD (AMD.US) shed more than 3%. Micron (MU.US) slid 4%. Intel (INTC.US), with the White House as a shareholder, inched down less than 1%.

US officials drafted regulatory proposals that will require companies to obtain government permission before exporting AI accelerators, affecting products from companies like NVIDIA and AMD, sources divulged. If implemented, the measures will expand the current restrictions, which apply to about 40 countries, to the whole world.

(me/t)~

AASTOCKS Financial News
Website: www.aastocks.com

Concerns over the Iran war intensified again, pushing New York oil futures above USD80 per barrel, and leading to a sell-off in US stocks on Thursday.

The DJIA tumbled incessantly, last plummeting 1,020 points or 2.1%, to 47,719. The Nasdaq slipped 280 points or 1.3%, to 22,524. The S&P 500 fell 91 points or 1.3%, to 6,778.

Traditional stocks were subdued, with Boeing (BA.US) diving over 3% and Caterpillar (CAT.US) nearly 5%. Techs NVIDIA (NVDA.US), Apple (AAPL.US), and Tesla (TSLA.US) all lost over 1%.
~



AASTOCKS Financial News
Website: www.aastocks.com

BARCELONA, Spain, March 5, 2026 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, and Türk Telekom have jointly completed the world's first C+L (12 THz) full-band integrated 1.6Tbps live network trial in Istanbul. The trial has significantly boosted system capacity, reduced spare part types, and enabled ultra-high-speed 400GE/800GE service transmission, laying a solid foundation for Türkiye to develop ultra-broadband and intelligent all-optical networks, thereby elevating the digital economy level of Türkiye and even Eurasia.

To address the rapidly growing demand for data traffic, Türk Telekom and ZTE conducted a transcontinental live network traffic trial in Istanbul, deploying ZTE's C+L full-band integrated 1.6Tbps solution. This solution supports seamless switching between the C-band and L-band via a unified management system, with no physical network modifications required. While fully leveraging existing fiber infrastructure, it achieves efficient utilization of the full optical spectrum, building a cost-effective, high-capacity, and highly flexible optical network architecture to support rapid response to traffic growth and meet future high-speed network demands.

The trial also introduced a new intelligent network management system, relying on a holographic optical solution with capabilities in optical sensing, provisioning, diagnosis, and optimization, achieving full visibility, manageability, and controllability of the network. Through intelligent functions such as transport capacity mapping, network health assessment, fault diagnosis analysis and the same optical cable and same route, it enables full lifecycle management of network resources, real-time visibility of alarms and performance data, and proactive prevention of potential risks, significantly reducing fault resolution time and enhancing network operational efficiency and stability.

Ebubekir Şahin, Chief Executive Officer of Türk Telekom, said, ''This groundbreaking trial carried out with ZTE represents another milestone in Türk Telekom's ongoing leadership in building Türkiye's most advanced optical transmission infrastructure. In a trial conducted in collaboration with ZTE, we proved that we can rapidly increase capacity in areas where it is needed without having to replace the entire network, setting another world's first. With this move, we will implement a flexible, low-cost, and sustainable infrastructure model that can quickly respond to increases in data traffic and meet the high-speed needs of the future.''

Ling Zhi, Vice President of ZTE, said, ''This world's first C+L full-band integrated 1.6Tbps live network trial with Türk Telekom demonstrates how ZTE's globally proven optical transmission and AI-driven network management technologies can be successfully applied within Türkiye's critical infrastructure. By delivering higher capacity, simplified hardware architecture and autonomous operational capabilities, we are paving the way for next–generation optical networks for HI-OTN (High Intelligence and High Performance) that accelerate the country's digital transformation.''

For more information, please visit the ZTE booth (3F30, Hall 3, Fira Gran Via) at MWC Barcelona 2026 or explore: https://www.zte.com.cn/global/about/exhibition/mwc26.html

MEDIA INQUIRIES:

ZTE Corporation
Communications
Email: [email protected] 

According to the Hurun Global Rich List 2026 released by the Hurun Research Institute, Tesla (TSLA.US) founder Elon Musk has become the world's richest person for the fifth time in six years. His wealth soared by 89% over the past year, reaching RMB5.5 trillion.

Ranking second was Amazon (AMZN.US) founder Jeff Bezos. His wealth amounted to RMB2.1 trillion. Alphabet (GOOGL.US) co-founders Larry Page and Sergey Brin ranked third and fifth, and they saw their wealth increase by 65% and 67%, respectively.

Among Chinese entrepreneurs, ByteDance founder Zhang Yiming became China's richest person with wealth increasing by 32% to RMB550 billion. NONGFU SPRING (09633.HK) founder Zhong Shanshan ranked second with RMB515 billion, followed by TENCENT (00700.HK) chairman Pony Ma with RMB465 billion.

CATL (03750.HK) chairman Robin Zeng occupied the fourth spot with wealth growing by 46% to RMB380 billion. Lei Jun and the Jack Ma family are tied for tenth with RMB230 billion.
~



AAStocks Financial News
Web Site: www.aastocks.com

SK Group Chairman Chey Tae-won will attend Nvidia(NVDA.US)'s GTC this month, where he is anticipated to discuss AI chip collaboration with Nvidia CEO Jensen Huang, according to Korean media.

At this year's GTC, Nvidia is expected to unveil its next-generation AI accelerator platform, Vera Rubin, which will utilize HBM4. The report noted that Nvidia has already allocated approx. two-thirds of its HBM4 orders to SK Hynix this year.

During the meeting, Chey and Huang will discuss a range of strategic cooperation areas, including HBM4 supply coordination, joint development of next-generation HBM technology, and potential collaboration in AI data centers and energy infrastructure, sources added.
~


AASTOCKS Financial News
Website: www.aastocks.com

西班牙巴塞羅那2026年3月5日 /美通社/ -- 近日，土耳其電信聯合中興通訊在伊斯坦布爾完成全球首個C+L（12THz）全頻一體化1.6Tbps優智全光網現網試驗，大幅提升系統容量、減少備件種類，並實現400GE/800GE業務超高速傳輸，為土耳其發展超寬、智能化全光網絡、提升土耳其乃至歐亞數字經濟水平奠定堅實基礎。

為應對數據流量持續高速增長的需求，土耳其電信與中興通訊在伊斯坦布爾成功開展洲際現網流量測試。本次測試采用中興通訊C+L 全頻一體化 1.6Tbps 解決方案，可通過集中管理系統實現 C 波段與 L 波段無縫協同切換，無需對網絡進行物理改造，在充分復用現有光纖基礎設施的同時，實現全頻譜資源高效利用，助力構建低成本、大容量、高靈活的新一代光網絡架構，為快速響應流量激增、支撐未來高速網絡發展提供堅實保障。

此次試驗同步引入全新智能網管系統，依托具備光感知、光開通、光診斷、光優化能力的全息光解決方案，實現網絡全方位可視、可管、可控。通過運力地圖可視化、網絡健康度評估、故障診斷分析、光纜同纜同路由等智能化功能，實現網絡資源狀態全周期可管、告警與性能數據實時可視，潛在風險和故障前瞻性可控，大幅縮短故障處理時長，提升網絡運行效率與穩定性。

土耳其電信CEO Ebubekir Şahin表示：「與中興通訊合作的這項突破性試驗，是土耳其電信打造最先進光傳輸基礎設施的又一裡程碑。我們證明了無需替換整個網絡，即可快速提升區域容量，再次創造世界第一，這將幫助我們構建靈活、低成本、可持續的基礎設施，響應流量增長與未來高速業務需求。」

中興通訊副總裁凌志表示：「與土耳其電信攜手完成的這項全球首個C+L全頻一體化1.6Tbps現網試點，充分展現了中興通訊經全球驗證的光傳輸技術與AI驅動的網絡管理技術，能夠成功應用於土耳其的關鍵基礎設施。我們通過提供更高容量、簡化的硬件架構及自主運維能力，為下一代HI-OTN優智全光網絡奠定基礎，助力土耳其加速數字轉型進程。」

媒體咨詢:
ZTE Corporation
Communications
Email: [email protected]

HONG KONG and SHANGHAI, March 5, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group"; HKEX: 2318/82318; SSE: 601318) has coordinated its subsidiaries, including Property & Casualty insurance ("P&C"), Life and Health insurance ("Life & Health"), and Ping An Bank, in response to the recent escalation of tensions in the Middle East. The Group promptly issued early warning notifications and evacuation recommendations to customers stranded in the region, while simultaneously gathering information on personnel status and customer needs in high-risk areas.

Ping An Global Emergency Assistance Service Center has been alerting customers to potential risks and distributed targeted risk analysis reports. To date, the Group has issued a total of 59 risk warnings, 23 risk analysis reports, and handled 52 customer inquiries. Notably, it facilitated the safe evacuation of two employees of corporate clients from high-risk areas in the Middle East within 24 hours.

Continued Support for Customers

Ping An remains vigilant in monitoring customers' situations in high-risk regions, ready to deploy global resources at a moment's notice to address any emergency needs and provide support to Mainland Chinese citizens in conflict zones.

On January 12, Ping An issued a high‑risk advisory and began providing timely alerts to customers in the Middle East. It carried out thorough risk assessments and prepared evacuation resources to ensure rapid support whenever needed.

The Group will continue to closely monitor developments in high-risk areas and ensure immediate responses to assistance requests. Whether you are a Ping An customer or not, help is available by calling the emergency hotline at 95511 (from overseas: +86 755 95511).

About Ping An Insurance (Group) Company of China, Ltd.

Ping An Insurance (Group) Company of China, Ltd. (HKEX:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services. Under the technology-enabled "integrated finance + health and senior care" dual-pronged strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its nearly 250 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of December 2024, Ping An had more than RMB12 trillion in total assets. The Group ranked 27th in the Forbes Global 2000 list in 2025, 47th in the Fortune Global 500 list in 2025, and ranked AAA in MSCI ESG Ratings in 2025.

For more information, please visit the www.group.pingan.com and follow our LinkedIn page - PING AN.

Goldman Sachs has released a research report predicting that Broadcom (AVGO.US) will see its stock price, supported by the excellent performance of its AI semiconductors, rise mildly following the release of its strong quarterly results and market-beating guidance.

In line with upward revisions in capital expenditures by major AI clients, Broadcom's guidance for 2Q26 AI semiconductor revenue is 15% higher than market expectations, indicating continued growth in both XPU and networking businesses.

Goldman Sachs has given Broadcom a Buy rating and a target price of USD450.
~



AAStocks Financial News
Web Site: www.aastocks.com

HONG KONG, March 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent or metastatic cervical cancer (R/M CC) who have failed prior platinum-containing chemotherapy, were presented in a late-breaking oral presentation by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, the Principal Investigator, at the 27th European Congress on Gynaecological Oncology (ESGO 2026).

The long-term survival data of cadonilimab monotherapy in this patient population confirms cadonilimab's ability to convert deep tumor remission into long-term disease control and survival benefits. This study provides clinically meaningful evidence to support its use in the treatment of advanced cervical cancer, offering patients a new therapeutic option that significantly improves survival outcomes.

Best Overall Response (BOR) Analysis Demonstrates Remarkable Survival Benefit

In the updated data presented at the ESGO Congress, with a median follow-up duration of 26.5 months, a BOR-stratified analysis was conducted in all 99 efficacy-evaluable patients. This analysis further quantified the strong correlation between the depth of tumor response and long-term survival benefit associated with cadonilimab treatment.

Among all subjects who achieved a complete response (CR), the median overall survival (OS) was not reached (NR), with a 24-month OS rate of up to 100.0% (nominal p = 0.0002). The median progression-free survival (PFS) was also not reached, with a 12-month PFS rate of 84.6% (nominal p < 0.0001).

In patients achieving partial response (PR), the median OS remained unreached (NR), with a 24-month OS rate of 63% (nominal p = 0.0002). The median PFS was 11.17 months, and the 12-month PFS rate was 47.3% (nominal p < 0.0001).

The median time to response (mTTR) in the CR patients was 1.84 months, comparable to that observed in the PR patients (1.87 months). The median duration of response (mDoR) in the CR patients was not reached and was significantly longer than that in the PR patients (nominal p = 0.035).

Cadonilimab Provides Sustained Long-Term Survival Benefit Irrespective of PD-L1 Expression Status

The COMPASSION-03 study enrolled more than 18% of patients with PD-L1 CPS < 1, and 36% of participants had received ≥2 prior lines of systemic therapy. Study findings demonstrated that cadonilimab monotherapy achieved a median OS of 17.5 months (11.4, NE).

Updated long-term follow-up data showed durable survival benefit across the overall population, including both PD-L1 positive and PD-L1 negative patients, with 18-month and 24-month OS rates of 47.8% and 40.9%, respectively.

The Rising Value of a Foundational IO 2.0 Backbone

Cadonilimab, the world's first approved cancer immunotherapy bispecific antibody that was commercially launched in 2022, has demonstrated its breakthrough clinical value across a large number of approved indications and Phase III trials. Cadonilimab addresses critical clinical gaps by benefiting cancer patients across all levels of PD-L1 expressions, earning strong recognition from clinicians and patients. Importantly, cadonilimab shows superior efficacy versus current standard of care in challenging settings like immunotherapy-resistant tumors and cold tumors that had limited response to PD-1/L1 agents.

This differentiated profile stems from its dual targeting of PD-1 and CTLA-4 with synergistic anti-tumor activity. This novel mechanism preserves the therapeutic benefits of both targets while overcoming their individual limitations. Specifically, the toxicity that restricts the clinical utility of current CTLA-4 monotherapy agents, and the poor response to PD-1/L1 agents in PD-L1 low/negative populations.

Cadonilimab is now approved for three indications in China: first-line gastric cancer, first-line cervical cancer, and recurrent/metastatic cervical cancer. It is under evaluation in 11 registrational/Phase III studies across major first-line tumor indications, various cold tumors, and IO-resistant settings, including a global Phase III trial in first-line gastric cancer and a global registrational trial in IO-resistant hepatocellular carcinoma.

While advancing cadonilimab's global clinical development independently, Akeso remains committed to open collaboration, integrating premier worldwide resources to accelerate international market access and benefit cancer patients worldwide.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.